Pub Date : 2023-11-07DOI: 10.1007/s12254-023-00918-w
Jasmin Spiegelberg
Summary Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancer. This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held from 2–6 June 2023, in Chicago, USA. Combination therapies for advanced RCC continue to be of interest at ASCO 2023, with the presentation of updated results from some ongoing studies. There were several studies presented at ASCO looking at treatments for non clear renal cell carcinoma. Immunotherapy- based therapy regimes are now the gold standard for rare histological subtypes of RCC.
{"title":"Renal cell carcinoma","authors":"Jasmin Spiegelberg","doi":"10.1007/s12254-023-00918-w","DOIUrl":"https://doi.org/10.1007/s12254-023-00918-w","url":null,"abstract":"Summary Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancer. This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held from 2–6 June 2023, in Chicago, USA. Combination therapies for advanced RCC continue to be of interest at ASCO 2023, with the presentation of updated results from some ongoing studies. There were several studies presented at ASCO looking at treatments for non clear renal cell carcinoma. Immunotherapy- based therapy regimes are now the gold standard for rare histological subtypes of RCC.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"30 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135475911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-03DOI: 10.1007/s12254-023-00921-1
Katharina Reiter, Melanie R. Hassler
Summary Prostate cancer (PCa) is an androgen-receptor signaling-dependent disease with a subset of patients harboring pathogenic germline variants (PGVs) in genes essential for DNA repair. In the last decade, several guidelines and recommendations have been developed to define which PCa patients should receive genetic testing to identify individuals at higher risk due to inherited alterations and to facilitate personalized treatment strategies. Notably, the presence of specific germline alterations in carriers undergoing PCa screening has implications for screening strategies, and PGV carriers with advanced disease are eligible to receive targeted therapies such as poly-ADP-ribose polymerase inhibitors (PARPi) or immune checkpoint inhibitors (CKI) depending on the alterations encountered. Although less information is available on carriers with localized disease, several trials are addressing this specific patient population and will help to collect data and improve clinical management of PCa patients with PGVs.
{"title":"Genetic testing and management of prostate cancer patients with pathogenic germline variants","authors":"Katharina Reiter, Melanie R. Hassler","doi":"10.1007/s12254-023-00921-1","DOIUrl":"https://doi.org/10.1007/s12254-023-00921-1","url":null,"abstract":"Summary Prostate cancer (PCa) is an androgen-receptor signaling-dependent disease with a subset of patients harboring pathogenic germline variants (PGVs) in genes essential for DNA repair. In the last decade, several guidelines and recommendations have been developed to define which PCa patients should receive genetic testing to identify individuals at higher risk due to inherited alterations and to facilitate personalized treatment strategies. Notably, the presence of specific germline alterations in carriers undergoing PCa screening has implications for screening strategies, and PGV carriers with advanced disease are eligible to receive targeted therapies such as poly-ADP-ribose polymerase inhibitors (PARPi) or immune checkpoint inhibitors (CKI) depending on the alterations encountered. Although less information is available on carriers with localized disease, several trials are addressing this specific patient population and will help to collect data and improve clinical management of PCa patients with PGVs.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"50 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135819447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-03DOI: 10.1007/s12254-023-00919-9
Clemens Petrasch, Petra Marics, Thomas Spanberger
{"title":"Management of malignant hypercalcemia in cancer patients—a short review","authors":"Clemens Petrasch, Petra Marics, Thomas Spanberger","doi":"10.1007/s12254-023-00919-9","DOIUrl":"https://doi.org/10.1007/s12254-023-00919-9","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"11 3‐4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135820266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-27DOI: 10.1007/s12254-023-00928-8
Sophie Roider-Schur, Sybille Machat, Leopold Öhler
{"title":"Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction","authors":"Sophie Roider-Schur, Sybille Machat, Leopold Öhler","doi":"10.1007/s12254-023-00928-8","DOIUrl":"https://doi.org/10.1007/s12254-023-00928-8","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"11 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136316455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-27DOI: 10.1007/s12254-023-00929-7
Angela Djanani
Summary Two exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients.
{"title":"ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma","authors":"Angela Djanani","doi":"10.1007/s12254-023-00929-7","DOIUrl":"https://doi.org/10.1007/s12254-023-00929-7","url":null,"abstract":"Summary Two exciting phase 2 dates were presented at Asco. This results in a new phase III study for Hepatocelluar cancer that will be launched soon. With Cholangiocarcinoma there is a new substance that shows very good oberall response rates in a subgroup of patients.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136311461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-19DOI: 10.1007/s12254-023-00927-9
Sazan Rasul, Stephan Korn
Summary In Europe, it is estimated that more than 65,000 men die each year from the consequences of advanced and metastatic prostate cancer (PCa). Currently, approximately 3.2 million European men are living with PCa. While the majority of PCa patients have favorable outcomes, the 5‑year relative survival rate for those with metastatic PCa is only 32%. Recent advances in the diagnosis of PCa have been boosted by the introduction of the prostate-specific membrane antigen (PSMA), which might identify patients with the most aggressive form of the disease. Molecular imaging with positron emission tomography (PET) targeting PSMA receptors (PSMA-PET) has utterly revolutionized the diagnosis and staging of PCa; however, its application is still under debate. On the one hand, there has been little progress in recent years in surpassing the limitations of androgen deprivation therapy (ADT), the backbone of metastatic PCa treatment. Adding additional systemic therapy became standard in the last few decades. Current ADT is only transiently effective, and patients eventually progress during ADT treatment, a condition known as castration-resistant PCa (CRPC). On the other hand, radioligand therapy (RLT) targeting these PSMA receptors, most commonly used in the studies [ 177 Lu]lutetium-PSMA-617, has been available for this cancer stage for nearly a decade and has been recently incorporated into the European Association of Urology (EAU) guidelines as a robust treatment option for patients with metastatic CRPC.
{"title":"Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment","authors":"Sazan Rasul, Stephan Korn","doi":"10.1007/s12254-023-00927-9","DOIUrl":"https://doi.org/10.1007/s12254-023-00927-9","url":null,"abstract":"Summary In Europe, it is estimated that more than 65,000 men die each year from the consequences of advanced and metastatic prostate cancer (PCa). Currently, approximately 3.2 million European men are living with PCa. While the majority of PCa patients have favorable outcomes, the 5‑year relative survival rate for those with metastatic PCa is only 32%. Recent advances in the diagnosis of PCa have been boosted by the introduction of the prostate-specific membrane antigen (PSMA), which might identify patients with the most aggressive form of the disease. Molecular imaging with positron emission tomography (PET) targeting PSMA receptors (PSMA-PET) has utterly revolutionized the diagnosis and staging of PCa; however, its application is still under debate. On the one hand, there has been little progress in recent years in surpassing the limitations of androgen deprivation therapy (ADT), the backbone of metastatic PCa treatment. Adding additional systemic therapy became standard in the last few decades. Current ADT is only transiently effective, and patients eventually progress during ADT treatment, a condition known as castration-resistant PCa (CRPC). On the other hand, radioligand therapy (RLT) targeting these PSMA receptors, most commonly used in the studies [ 177 Lu]lutetium-PSMA-617, has been available for this cancer stage for nearly a decade and has been recently incorporated into the European Association of Urology (EAU) guidelines as a robust treatment option for patients with metastatic CRPC.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135778691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-19DOI: 10.1007/s12254-023-00924-y
Aysegül Ilhan-Mutlu, Ewald Wöll
Summary There is an unmet need for the treatment of patients with HER2-positive gastroesophageal tumors whose disease progressed on a first-line trastuzumab-based regimen. Several prospective trials took a targeted approach and evaluated various HER2-targeted agents as second-line therapy. However, these trials failed to demonstrate a survival benefit and were negative in primary endpoints. Recently, the antibody–drug conjugate trastuzumab deruxtecan has shown promise as a second-line treatment in patients with HER2-positive metastatic gastroesophageal tumors, with a remarkable overall response rate and a relevant prolongation of prognostic outcome. Several clinical trials will introduce more targeted therapy approaches with novel structures, which will hopefully further extend patients’ survival. This mini-review briefly summarizes the past practice of second-line treatment of HER2-positive gastroesophageal tumor patients, describes current knowledge based on recently published studies, and provides a short overview on the novel anti-HER2 compounds that are currently being clinically investigated and could yield positive results in the near future.
{"title":"Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma","authors":"Aysegül Ilhan-Mutlu, Ewald Wöll","doi":"10.1007/s12254-023-00924-y","DOIUrl":"https://doi.org/10.1007/s12254-023-00924-y","url":null,"abstract":"Summary There is an unmet need for the treatment of patients with HER2-positive gastroesophageal tumors whose disease progressed on a first-line trastuzumab-based regimen. Several prospective trials took a targeted approach and evaluated various HER2-targeted agents as second-line therapy. However, these trials failed to demonstrate a survival benefit and were negative in primary endpoints. Recently, the antibody–drug conjugate trastuzumab deruxtecan has shown promise as a second-line treatment in patients with HER2-positive metastatic gastroesophageal tumors, with a remarkable overall response rate and a relevant prolongation of prognostic outcome. Several clinical trials will introduce more targeted therapy approaches with novel structures, which will hopefully further extend patients’ survival. This mini-review briefly summarizes the past practice of second-line treatment of HER2-positive gastroesophageal tumor patients, describes current knowledge based on recently published studies, and provides a short overview on the novel anti-HER2 compounds that are currently being clinically investigated and could yield positive results in the near future.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135730219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-17DOI: 10.1007/s12254-023-00917-x
Giuseppe A. Colloca, Antonella Venturino
{"title":"Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis","authors":"Giuseppe A. Colloca, Antonella Venturino","doi":"10.1007/s12254-023-00917-x","DOIUrl":"https://doi.org/10.1007/s12254-023-00917-x","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136032972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-13DOI: 10.1007/s12254-023-00916-y
Julia M. Berger, Pia Gattinger, Maximilian J. Mair, Anna S. Berghoff, Rudolf Valenta, Matthias Preusser
Summary This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed.
{"title":"Cellular and humoral responses to fourth SARS-CoV-2 vaccination in a real-life cohort of patients with cancer","authors":"Julia M. Berger, Pia Gattinger, Maximilian J. Mair, Anna S. Berghoff, Rudolf Valenta, Matthias Preusser","doi":"10.1007/s12254-023-00916-y","DOIUrl":"https://doi.org/10.1007/s12254-023-00916-y","url":null,"abstract":"Summary This study assessed cellular and humoral responses to the fourth dose of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with malignant diseases. Even though, clear indications of humoral, cellular, or combined response was evident in most patients undergoing active treatment, high intra- and interpatient heterogeneity in response patterns was observed.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135856254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.1007/s12254-023-00895-0
Alexandra Böhm
{"title":"Long-term survival and follow-up care after cancer in Austria","authors":"Alexandra Böhm","doi":"10.1007/s12254-023-00895-0","DOIUrl":"https://doi.org/10.1007/s12254-023-00895-0","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135305087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：